JOHN COOK: Open Payments
NPI 1578030813 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,934 in 17 payments from 13 companies in 2025. Trend: 2023 $1,987 · 2024 $691 · 2025 $1,934
Food & beverage: $1,934
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $340 |
| Janssen Pharmaceuticals, Inc | 3 | $322 |
| Abbott Laboratories | 1 | $146 |
| ABIOMED | 1 | $126 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Corcept Therapeutics | 1 | $123 |
| Gilead Sciences, Inc. | 1 | $122 |
| LivaNova USA, Inc. | 1 | $112 |
| E.R. Squibb & Sons, L.L.C. | 1 | $108 |
Products named: SPRAVATO, INVEGA, PROCLAIM, CAPLYTA, ABILIFY MAINTENA, Korlym, INGREZZA, Livdelzi.
Industry payments across TX — which companies pay providers there.
